Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma
Conditions
Keywords
Iressa, ZD1839, Anastrozole, Arimidex
Brief summary
The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.
Detailed description
* Patients will receive Iressa and anastrozole orally once daily until treatment is ended. Treatment will end if any of the following occur: Unacceptable adverse effects; bowel obstruction; initiation of systemic chemotherapy; development of new ascites or pleural effusions, development of co-morbid disease or disease progression. * Patients will be given a drug log in which to record the date and time they take their pills, as well as any symptoms and concomitant medications. * Patients will be seen monthly for the following tests and procedures; a physical examination and repeat blood work. Patients who remain free of clinical symptoms should have repeat abdominal/pelvic CT scans and chest x-rays on an every 3 month basis.
Interventions
Sponsors
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic history diagnosis of primary ovarian, primary peritoneal or tubal carcinoma * Asymptomatic from ovarian cancer * Evidence of recurrent ovarian, peritoneal or tubal carcinoma * Tumor sample must be positive for ER and/or PR * 18 years of age or older * ECOG performance status of less than or equal to 1 * Must be able to tolerate oral intake
Exclusion criteria
* Known hypersensitivity to Iressa or any of the excipients of this product * Other coexisting malignancies or malignancies diagnosed within the last 5 years * Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital or St. John's wort * Treatment with a non-approved or investigational drug within 30 days * Any unresolved chronic toxicity greater than CTC grad 2 from previous anticancer therapy (except alopecia) * Incomplete healing from previous oncologic or other major surgery * Serum creatinine level greater than CTC grade 2 * Pregnant or breast feeding * Severe uncontrolled systemic disease * Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate * Patients currently receiving other investigational antineoplastic agents, on systemic chemotherapy or under radiation therapy treatment * Patients previously treated with anastrozole or other aromatase inhibitor * Unable to tolerate oral medications * Clinical and/or radiographic evidence of current or impending bowel obstruction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To define the median time to termination of treatment with Iressa and anastrozole in patients with asymptomatic relapsed ovarian cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| To define the median time to progression of this patient population | — |
| to assess the tumor response and safety of this treatment. | — |
Countries
United States
Outcome results
None listed